The estimated Net Worth of Santosh T Varghese is at least $732 Tausend dollars as of 3 April 2018. Mr. Varghese owns over 390 units of VIVUS stock worth over $33,315 and over the last 9 years he sold VVUS stock worth over $69,196. In addition, he makes $629,372 as Senior Vice President und Chief Medical Officer at VIVUS.
Santosh has made over 16 trades of the VIVUS stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 390 units of VVUS stock worth $133 on 3 April 2018.
The largest trade he's ever made was selling 13,790 units of VIVUS stock on 31 December 2016 worth over $15,445. On average, Santosh trades about 2,282 units every 42 days since 2015. As of 3 April 2018 he still owns at least 71,415 units of VIVUS stock.
You can see the complete history of Mr. Varghese stock trades at the bottom of the page.
Santosh T. Varghese M.D. serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Varghese has served as our Senior Vice President, Chief Medical Officer since February 2020. From January 2016 until February 2020, Dr. Varghese served as our Chief Medical Officer. Dr. Varghese served as our Vice President, Medical & Regulatory Affairs, Pharmacovigilance, and QA from October 2013 until December 2015, as our Vice President, Head of Medical Affairs, Pharmacovigilance, and Regulatory Compliance from July 2013 until October 2013, as our Vice President, Head of Medical Affairs and Pharmacovigilance from April 2012 until July 2013, and as our Vice President, Head of Medical Affairs from March 2012 until April 2012. Prior to this, Dr. Varghese was Senior Vice President, Medical Affairs at Elan Pharmaceuticals, a biopharmaceutical company, from January 2011 until March 2012. From April 2010 until January 2011, Dr. Varghese served as an executive consultant in the pharmaceutical industry for medical education and pharmaceutical companies. From June 2008 until April 2010, he was Vice President Primary Care & Cardiovascular in Global Medical Affairs at Schering-Plough Corporation (now Merck & Co.), a pharmaceutical company, in addition to other senior roles at Schering-Plough Corporation from May 2006 until June 2008. From November 2000 until May 2006, he held senior roles at Aventis and Sanofi-Aventis (now Sanofi SA), a pharmaceutical company. Dr. Varghese previously served on the board of directors of the American Lung Association—New York, and was an Adjunct Associate Professor at Touro University College of Medicine (now New York Medical College). Dr. Varghese is the co-author of abstracts and journal publications in multiple therapeutic areas. Dr. Varghese holds a B.S. in Biology from Pennsylvania State University and an M.D. from St. George's University School of Medicine. He completed his medical training in the Caribbean, United States, and United Kingdom.
As the Senior Vice President und Chief Medical Officer of VIVUS, the total compensation of Santosh Varghese at VIVUS is $629,372. There are 2 executives at VIVUS getting paid more, with John Amos having the highest compensation of $873,894.
Santosh Varghese is 49, he's been the Senior Vice President und Chief Medical Officer of VIVUS since 2020. There are 9 older and no younger executives at VIVUS. The oldest executive at VIVUS, Inc. is Edward Kangas, 75, who is the Independent Director.
Santosh's mailing address filed with the SEC is C/O VIVUS, INC., 900 E. HAMILTON AVE., SUITE 550, CAMPBELL, CA, 95008.
Over the last 21 years, insiders at VIVUS have traded over $6,261,269 worth of VIVUS stock and bought 5,180,746 units worth $13,074,554 . The most active insiders traders include Tide Capital, Llc North Tid..., Alexander J Denner und Ernest Mario. On average, VIVUS executives and independent directors trade stock every 39 days with the average trade being worth of $35,394. The most recent stock trade was executed by John P. Amos on 1 March 2019, trading 11,000 units of VVUS stock currently worth $53,350.
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.
VIVUS executives and other stock owners filed with the SEC include: